Skip to main content
Atrás
Watch Compare

Caribou Biosciences, Inc.

Calidad de datos: 100%
CRBU
NASDAQ Manufacturing Chemicals
$1.95
▲ $0.02 (1.04%)
Cap. Mercado: 190.38 M
Precio
$1.97
Cap. Mercado
190.38 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Revenue grew 3.84% annually over 5 years — modest growth
Negative free cash flow of -112.35 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7.82%

Crecimiento

Revenue Growth (5Y)
3.84%
Above sector avg (1.82%)
Revenue (1Y)11.66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-96.19%
Below sector avg (-54.44%)
ROIC-65.30%
Net Margin-1327.40%
Op. Margin-1329.37%

Seguridad

Debt / Equity
N/A
Current Ratio5.54
Interest CoverageN/A

Valoración

PE (TTM|NTM)
-1.29 | -1.29
Above sector avg (-1.49)
P/B Ratio1.34
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1385 pares)
Métrica Acción Mediana del Sector
P/E -1.3 -1.5
P/B 1.3 1.6
ROE % -96.2 -54.4
Net Margin % -1327.4 -41.5
Rev Growth 5Y % 3.8 1.8
D/E — 0.3

Precio Objetivo de Analistas

8 analistas
Buy
Actual
$1.95
+470.5%
Objetivo
$11.13
$4.00
$8.50
$32.00
Pronóstico
P/E Futuro -1.29
EPS Futuro -$1.50
Ingresos Est. 27.08 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$1.50
-$1.50 – -$1.50
 27.08 M 1
FY2026 -$1.38
-$1.38 – -$1.38
 23.70 M 1

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.32 -$0.28 +12.9%
Q32025 -$0.36 -$0.30 +16.0%
Q22025 -$0.42 -$0.35 +16.7%
Q12025 -$0.45 -$0.44 +2.2%

ETFs Holding This Stock

CNCR CNCR
1.02% weight
NXTE logo NXTE AXS Green Alpha ETF
0.79% weight
WDNA WDNA
0.31% weight
BRSIX BRSIX
0.08% weight
GSCYX GSCYX
0.02% weight
GSCZX GSCZX
0.02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 11.66% Revenue Growth (3Y) -43.11%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3.84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 11.16 M Net Income (TTM) -148.13 M
ROE -96.19% ROA -71.23%
Gross Margin N/A Operating Margin -1329.37%
Net Margin -1327.40% Free Cash Flow (TTM) -112.35 M
ROIC -65.30% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.54
Interest Coverage N/A Asset Turnover 0.05
Working Capital 127.45 M Tangible Book Value 141.85 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.29 Forward P/E -1.29
P/B Ratio 1.34 P/S Ratio 17.06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 7.03 Fwd Earnings Yield N/A
FCF Yield -59.02%
Market Cap 190.38 M Enterprise Value 179.23 M
Per Share
EPS (Diluted TTM) -1.59 Revenue / Share 0.12
FCF / Share -1.16 OCF / Share -1.15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 12.18% FCF Conversion 75.85%
SBC-Adj. FCF -126.36 M Growth Momentum 7.82

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 11.16 M 9.99 M 34.48 M 13.85 M 9.60 M
Net Income -148.13 M -149.11 M -102.07 M -99.42 M -66.92 M
EPS (Diluted) -1.59 -1.65 -1.38 -1.64 —
Gross Profit — — — — —
Operating Income -148.34 M -166.62 M -116.06 M -106.40 M -66.98 M
EBITDA — — — — —
R&D Expenses 109.44 M 130.15 M 112.08 M 82.23 M 52.26 M
SG&A Expenses — — — — —
D&A 3.65 M 3.93 M 3.53 M 1.62 M 984,000.0
Interest Expense — — — — 8,000.0
Income Tax -550,000.0 -9,000.0 193,000.0 70,000.0 321,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 175.37 M 313.31 M 432.21 M 373.77 M 442.36 M
Total Liabilities 53.19 M 60.36 M 63.81 M 72.89 M 54.53 M
Shareholders' Equity 122.18 M 252.95 M 368.40 M 300.87 M 387.83 M
Total Debt — — — — —
Cash & Equivalents 12.36 M 16.29 M 51.16 M 58.34 M 240.42 M
Current Assets 145.23 M 219.38 M 338.84 M 260.25 M 391.19 M
Current Liabilities 25.41 M 30.65 M 28.30 M 28.13 M 25.83 M